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Summary
What is already known on this topic?
Increased risk of all-cause mortality is associated with nonoptimal blood
pressure. However, studies of the relationship between blood pressure
categories and all-cause mortality in the Chinese adult population are lim-
ited, and sex-specific studies of these associations are not available. Fur-
thermore, the relationship between the 2017 US hypertension guidelines
and all-cause mortality in China is unclear.
What is added by this report?
Results of our prospective study, in a rural Chinese population, showed
that risk of all-cause mortality with hypertension based on the 2017 US hy-
pertension guidelines was increased for men but not women.
What are the implications for public health practice?
Treatment for hypertension should rely on clinicians’ cautious judgment
about whether and when to start treatment. In addition, antihypertension
goals may need to be individualized for people with different characterist-
ics.
Abstract
Introduction
The relationship between blood pressure categories and all-cause
mortality has not been fully addressed in cohort studies,  espe-
cially in the general Chinese population. Our study aimed to as-
sess the sex-specific association of systolic blood pressure (SBP),
diastolic blood pressure (DBP), and 2017 United States hyperten-
sion guidelines with all-cause mortality in China.
Methods
We conducted a prospective study of 13,760 rural Chinese adults
aged 18 or older (41.1% men). Mean age overall was 49.4, 51.0
for  men,  and  48.3  for  women.  We  analyzed  the  blood
pressure–mortality relationship by using restricted cubic splines
and Cox proportional-hazards regression analysis, estimating haz-
ard ratios (HRs) and 95% confidence intervals (CIs).
Results
During a mean follow-up of 5.95 years, 710 people died (60.3%
men) from any cause. We found a U-shaped SBP–mortality or
DBP–mortality relationship for both sexes. Mortality risk was in-
creased for men with SBP 120–139 mm Hg (adjusted HR [aHR],
1.42; 95% CI, 1.10–1.82) or ≥140 mm Hg (aHR, 2.05; 95% CI,
1.54–2.72),  and  for  DBP  ≥90  mm  Hg  (aHR,  1.53;  95%  CI,
1.10–2.13) as compared with SBP 100–119 mm Hg or DBP 70–79
mm Hg. Mortality risk also was increased for men with blood
pressure  status  defined  according  to  2017  US  hypertension
guidelines as elevated, SBP 120–129 and DBP >80 mm Hg (aHR
1.48;  95%  CI,1.11–1.98);  stage  1  hypertension,  SBP/DBP
130–139/80–89 mm Hg (aHR 1.53; CI, 1.19–1.97); and stage 2
hypertension,  SBP/DBP  ≥140/90  mm  Hg  (aHR  1.83;  CI,
1.33–2.51). No significant relationship was observed for women.
Conclusion
Elevated blood pressure and stages 1 and 2 hypertension were pos-
itively associated with all-cause mortality for men but not women
in rural China.
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Introduction
Nonoptimal blood pressure, which caused over 10 million deaths
worldwide in 2016, is the leading cause of global mortality (1,2).
Epidemiologic evidence has indicated a U- or J-shaped associ-
ation of systolic blood pressure (SBP) or diastolic blood pressure
(DBP) with all-cause mortality (2–4). Previous cohort studies in-
vestigated the SBP–mortality or DBP–mortality relationship in the
general  Chinese  population;  however,  study populations  were
mainly  coalminers,  urban women,  or  people  aged 65 or  older
(4–8). Also, to our knowledge, no other general population–based
studies have been made of the relationship between blood pres-
sure categories and all-cause mortality in China except for 2 co-
hort studies, 1 of adults aged 40 or older and 1 of urban women
(6,9). In addition, studies of Chinese adults that consider the po-
tential sex difference in the blood pressure–mortality relationship
are lacking (9,10).
The 2017 US hypertension guidelines recommend maintaining
blood pressure levels of SBP <130 mm Hg and DBP <80 mm Hg
in the general population (11); the guidelines lowered recommen-
ded blood pressure levels compared with previous US and Chinese
recommendations (12–14). Only 1 study, in Singapore — a popu-
lation that is not representative of mainland China — evaluated the
association between blood pressure categories and mortality on the
basis of 2017 US hypertension guidelines (15).
We conducted a prospective cohort study in a rural Chinese popu-
lation to elucidate the sex-specific association of baseline SBP and
DBP with all-cause mortality and also examined the association
between the 2017 US hypertension guidelines and all-cause mor-
tality in China.
Methods
Study participants
We conducted a prospective cohort study of 20,194 participants
aged 18 or older who were recruited from rural areas of Henan
Province in China for baseline examination (July–August 2007
and July–August 2008). During a mean follow-up of 5.95 years,
17,265 study participants were re-investigated, from July through
August 2013 and July through October 2014, with a response rate
of 85.5%. Details of the cohort were described previously (16).
After excluding people who used antihypertension medication or
whose data were incomplete for SBP or DBP at baseline examina-
tion (n = 3,505), the final cohort consisted of 13,760 eligible study
participants (41.1% men, n = 5,661) (Figure 1).
Figure 1. Flow diagram of participant selection, Sex-Specific Association of
Blood Pressure Categories With All-Cause Mortality: The Rural Chinese Cohort
Study,  2007–2014.  Abbreviations:  DBP,  diastolic  blood  pressure;  SBP,
systolic blood pressure.
All study participants gave their informed consent for inclusion
before the start of the study, and the study was approved by the
ethics committee of Zhengzhou University.
Baseline measurements. During face-to-face interviews, trained in-
terviewers administered a standard questionnaire to collect so-
ciodemographic information (sex, age, marital status, income, and
education level),  behavioral measures (smoking, drinking, and
physical activity), and medical history for all study participants.
Details regarding variables and the questionnaire for this cohort
have been published (16).
Smoking  was  classified  as  currently  smoking  and/or  having
smoked 100 or more cigarettes during their lifetime (17). Alcohol
drinking was defined as having consumed alcohol  12 or  more
times in the past year. Physical activity level was classified as low,
moderate, or high according to the International Physical Activity
Questionnaire (18).
Weight and height were measured twice according to a standard
protocol, weight to the nearest 0.1 kg and height to the nearest 0.1
cm, with study participants wearing light clothing but no shoes.
An average of the 2 measurements was used in our study. Body
mass index (BMI) was calculated as weight (kg) divided by height
(m) squared (19).
Blood pressure was measured 3 times at 30-second intervals in the
right arm after 5 minutes of rest with participants in a seated posi-
tion  by  using  an  electronic  sphygmomanometer  (HEM-
770AFuzzy, Omron, Kyoto, Japan) according to the American
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Heart Association standardized protocol. The average value of the
3 measurements was used for analyses (20).
Overnight fasting blood samples from each participant were col-
lected in vacuum tubes to assess levels of total cholesterol, trigly-
cerides, high-density lipoprotein cholesterol (HDL-C), and fasting
plasma glucose by using an automated biochemical analyzer (Hita-
chi 7080, Tokyo, Japan) with reagents from Wako Pure Chemical
Industries (Osaka, Japan).  Low-density lipoprotein cholesterol
(LDL-C) level  was calculated by using the Freidwald formula
(21).
Blood pressure categories. We classified SBP as <100 mm Hg,
100 to 119 mm Hg (reference), 120 to 139 mm Hg, and ≥140 mm
Hg (7,22), and DBP as <70 mm Hg, 70 to 79 mm Hg (reference),
80 to 89 mm Hg, and ≥90 mm Hg (23). To better characterize ac-
tual blood pressure levels and to evaluate the sex-specific associ-
ation of blood pressure with all-cause mortality, we further classi-
fied study participants into 4 groups according to the 2017 US hy-
pertension guidelines (11): normal blood pressure (SBP <120 mm
Hg and DBP <80 mm Hg), elevated blood pressure (SBP 120–129
mm  Hg  and  DBP  <80  mm  Hg),  stage  1  hypertension  (SBP
130–139 mm Hg or DBP 80–89 mm Hg), and stage 2 hyperten-
sion (SBP ≥140 mm Hg or DBP ≥90 mm Hg).
Mortality ascertainment during follow-up. We collected data on
time and cause of death by face-to-face interviews with relatives,
local village physicians, or other health care providers on the basis
of a standard questionnaire; we checked corresponding informa-
tion for death with the local Center for Disease Control and Pre-
vention. All-cause mortality was defined according to codes A00-
Z99 of the International Classification of Diseases, 10th Revision
(24).
Statistical analyses
Baseline data for study participants were median (interquartile
range) because of skewed distribution for continuous variables and
number  (percentage)  for  categorical  variables.  Differences  in
baseline characteristics by mortality status were compared by us-
ing the Mann–Whitney U test for continuous variables and χ2 test
for categorical variables. Person years of follow-up for each study
participant were computed by date of death or follow-up minus
baseline examination date.
We used restricted cubic splines to test a possible dose–response
association of SBP or DBP with all-cause mortality, by sex, at
baseline examination as a continuous variable. In addition, we
used Cox proportional-hazards regression analysis,  calculating
hazard ratios (HRs) and 95% confidence intervals (CIs). To avoid
potential bias and confirm primary findings, we performed addi-
tional sensitivity analyses because of a rapid decrease in strength
of the blood pressure–mortality association during the early fol-
low-up period (25); study participants who had died during the
first 2 years of follow-up (n = 143) were excluded from analyses.
We further excluded participants with myocardial infarction, heart
failure, stroke, diabetes mellitus, or cancer at baseline (n = 1,314)
because these diseases could have affected blood pressure and thus
the blood pressure–mortality relationship (2,26). All analyses were
adjusted at baseline examination for age; marital status; mean indi-
vidual  income (monthly);  education level;  smoking;  drinking;
physical activity; BMI; total cholesterol; triglycerides; HDL-C;
LDL-C; fasting plasma glucose; family history of hypertension,
diabetes mellitus, or hyperlipidemia; and use of hypoglycemic and
lipid-lowering medications.
All data were analyzed by using SAS version 9.4 (SAS Institute,
Inc), and figures were plotted by using Stata 12 software (Stata
Corp LLC). Statistical significance was set at a 2-tailed P < .05.
Results
Baseline characteristics of study participants. Among the 13,760
study participants at baseline examination, 41.1% (n = 5,661) were
men, and the median age was 49 (interquartile range, 40–59) (Ta-
ble).  During  a  mean  follow-up  of  5.95  years  (81,856  person
years), 710 deaths occurred. Of the 710 decedents, 428 (60.3%)
were men, 679 (95.6%) had less than a high school diploma, 540
(76.1%) were married or cohabiting; 264 (37.2%) were smokers,
69  (9.7%)  drank  alcohol,  684  (96.3%) had  a  mean individual
monthly  income  below  500  Chinese  yuan  (CNY),  and  364
(51.3%) had a low physical activity level. The median SBP of de-
cedents was 126.3 (interquartile range [IQR], 115.3–141.7); DBP,
76.3 (IQR, 69.0–84.3); total cholesterol, 4.5 (IQR, 3.9–5.1); LDL-
C, 2.6 (IQR 2.2–3.1); fasting plasma glucose, 5.4 (IQR, 5.0–6.0);
and lower BMI and HDL-C level (all P < .05). The median age of
decedents was 65.0 (IQR 57.0–73.0). Appendix Table 1 shows the
baseline characteristics of people included and excluded.
SBP–mortality relationship. We observed a slight U-shaped rela-
tionship between SBP at baseline examination and all-cause mor-
tality for men and women as a continuous variable after adjusting
for some potential confounders, although the 95% CIs for some
ranges of SBP or DBP were not significant. The lowest all-cause
mortality was associated with SBP of 113 mm Hg for men and
116 mm Hg for women (Figure 2). For men, risk of all-cause mor-
tality increased with SBP of 120–139 mm Hg (adjusted HR [aHR]
1.42; 95% CI, 1.10–1.82) or ≥140 mm Hg (aHR 2.05; 95% CI,
1.54–2.72) compared with SBP of 100 mm Hg to 119 mm Hg. We
did not find any relationship between SBP categories and all-cause
mortality for women (Figure 3). The results was consistent with
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Appendix Table 2, which also takes diabetes mellitus as the ad-
justment variable.
Figure 2. Adjusted risk trends for all-cause mortality by blood pressure level at
baseline examination on a continuous scale for men and women, adjusted for
age;  marital  status;  mean  individual  income  (monthly);  education  level;
smoking;  drinking;  physical  activity;  body  mass  index;  total  cholesterol;
triglycerides;  high-density  lipoprotein  cholesterol;  low-density  lipoprotein
cholesterol; fasting plasma glucose; family history of hypertension, diabetes
mellitus,  or  hyperlipidemia;  and  use  of  hypoglycemic  and  lipid-lowering
medications. Abbreviations: —, not applicable; aHR, adjusted hazard ratio; CI,
confidence  interval;  DBP,  diastolic  blood  pressure;  SBP,  systolic  blood
pressure.
Figure 3. All-cause mortality risk per 1,000 person years by blood pressure
categories at baseline examination in men and women based on the 2017 US
hypertension guidelines (11), adjusted for age; marital status; mean individual
income (monthly); education level; smoking; drinking; physical activity; body
mass  index;  total  cholesterol;  triglycerides;  high-density  lipoprotein
cholesterol; low-density lipoprotein cholesterol; fasting plasma glucose; family
history  of  hypertension,  diabetes  mellitus,  or  hyperlipidemia;  and use of
hypoglycemic and lipid-lowering medications. Abbreviations: aHR, adjusted
hazard ratio; CI, confidence interval.
The results did not change on sensitivity analyses after excluding
deaths occurring during the first 2 years of follow-up. On restrict-
ing the analyses to participants without pre-existing chronic dis-
ease (cardiovascular disease, diabetes mellitus, or cancer), results
were consistent with the initial analyses (Figure 3) except for a
significant association for men with SBP less than 100 mm Hg
(aHR 1.99; 95% CI, 1.11–3.58) (Figure 4). Further taking dia-
betes  mellitus  as  the  adjustment  variable,  the  results  did  not
change (Appendix Table 2).
Figure 4. All-cause mortality rate per 1,000 person years by blood pressure
categories based on the 2017 US hypertension guidelines (11) at baseline
examination for men and women on sensitivity analyses, adjusted for age;
marital status; mean individual income (monthly); education level; smoking;
drinking; physical activity; body mass index; total cholesterol; triglycerides;
high-density lipoprotein cholesterol; low-density lipoprotein cholesterol; fasting
plasma  glucose;  family  history  of  hypertension,  diabetes  mellitus,  or
hyperlipidemia;  and use  of  hypoglycemic  and lipid-lowering  medications.
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval.
DBP–mortality relationship. We assessed the DBP–mortality rela-
tionship by using continuous DBP at baseline and found a slight U
shape for both sexes, although the 95% CIs for some ranges of
SBP or DBP were not significant. The DBP levels associated with
the lowest all-cause mortality were 67 mm Hg for men and 73 mm
Hg for women (Figure 3). All-cause mortality was positively asso-
ciated with DBP of 80 mm Hg to 89 mm Hg (aHR 1.31; 95% CI,
1.02–1.69) or DBP ≥90 mm Hg (aHR 1.53; 95% CI, 1.10–2.13)
for men and DBP ≥90 mm Hg (aHR 1.50; 95% CI, 1.02–2.22) for
women compared with people with DBP 70 mm Hg to 79 mm Hg
(Figure 3). The results, further taking diabetes mellitus as the ad-
justment variable, were consistent with Appendix Table 2.
When we excluded study participants who died during the first 2
years of follow-up, we saw no change in the relationship between
DBP and mortality for men: however, we saw a marginal associ-
ation  for  women  with  DBP ≥90  mm Hg  (aHR 1.52;  95% CI,
0.99–2.32) (Figure 4A). When we further restricted analysis to
people free of the 5 pre-existing chronic diseases at baseline, res-
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ults were mostly similar to the initial analyses (Figure 3) for men
with DBP ≥90 mm Hg (aHR 1.76; 95% CI, 1.16–2.65); the rela-
tionship between DPB and mortality further weakened for women
with DBP at or above 90 mm Hg (aHR 1.51; 95% CI, 0.94–2.44)
(Figure 4B). However, the association between DBP and mortal-
ity disappeared for men with DBP 80 to 89 mm Hg (aHR 1.32;
95% CI, 0.95–1.84). Further taking diabetes mellitus as the adjust-
ment variable, the results did not change (Appendix Table 2).
Association of all-cause mortality with blood pressure categories
based on the 2017 US hypertension guidelines. For men, the risk
of all-cause mortality was higher and increased with increasing
blood pressure according to 2017 US hypertension guidelines:
with elevated blood pressure (aHR 1.48; 95% CI, 1.11–1.98), with
stage 1 hypertension (aHR 1.53; 95% CI, 1.19–1.97), or with stage
2 hypertension (aHR 1.83; 95% CI, 1.33–2.51) compared with
normal blood pressure. However, we found no significant relation-
ship for women between blood pressure categories and all-cause
mortality (Figure 3). The results were consistent with Appendix
Table 2, which also takes diabetes mellitus as the adjustment vari-
able.
When we excluded deaths that occurred during the first 2 years of
follow-up,  elevated  blood  pressure  (aHR  1.70;  95%  CI,
1.21–2.38), stage 1 hypertension (aHR 1.88; 95% CI, 1.41–2.50),
or stage 2 hypertension (aHR 2.17; 95% CI 1.51–3.14) were posit-
ively associated with all-cause mortality for men but not women
compared with normal blood pressure (Figure 4A), with increased
strength as compared with our initial analyses (Figure 3). On fur-
ther restricting the analysis to participants without any of the 5
pre-existing chronic diseases, risk of all-cause mortality was in-
creased for  men but  not  women with  blood pressure  status  as
defined by 2017 US hypertension guidelines as elevated blood
pressure (aHR 1.68; 95% CI, 1.15–2.44), stage 1 hypertension
(aHR 1.78; 95% CI, 1.29–2.46), or stage 2 hypertension (aHR
2.24; 95% CI 1.48–3.37) compared with normal blood pressure
(Figure 4B). Further taking diabetes mellitus as the adjustment
variable, the results did not change (Appendix Table 2).
Discussion
In this prospective cohort study of 13,760 eligible rural Chinese
adults, results suggested a U-shaped association of SBP or DBP
with all-cause mortality for both sexes. Men with SBP ≥120 mm
Hg, DBP ≥90 mm Hg, or SBP/DBP ≥130/80 mm Hg showed in-
creased risk of all-cause mortality. However, we found no signific-
ant relationship between SBP, DBP, or the 2017 US hypertension
guidelines categories and all-cause mortality for women.
Several  cohort  studies  indicated  a  positive  association  of  in-
creased mortality risk with low SBP level (<120 mm Hg/90 mm
Hg) or low DBP level (<80 mm Hg/40 mm Hg): the Korean Can-
cer Prevention Study, with 22.7 million person years of follow-up,
which included 1,329,525 people aged 30 to 95 (2); a retrospect-
ive community-based cohort study of 128,765 Taiwanese people
aged 65 or older followed for 3 years (4); and a prospective co-
hort study of 4,658 Chinese people aged 65 to 99 followed for 3
years (8). Other cohort studies suggested increased mortality risk
with high SBP level (≥120 mm Hg/160 mm Hg), high DBP level
(≥90 mm Hg), or SBP/DBP ≥120/80 mm Hg, 140/90 mm Hg, 160/
100 mm Hg (2,5,6,9,26,27).
Sex  differences  were  observed  in  published  cohort  studies
(2,6,7,28,29). Research data based on a cohort study from Korea
indicated high mortality risk for men with SBP ≥140 mm Hg or
<90 mm Hg and women with SBP ≥120 mm Hg (2). A Japanese
cohort study with 11-year follow-up included 33,372 men and wo-
men aged 40 to 69 who had no prior diagnosis of cancer or cardi-
ovascular disease. That study suggested increased mortality risk
for men with SBP/DBP ≥130/85 mm Hg but not for women (28).
However, a Swedish cohort study with 26-year follow-up that in-
cluded 2,280 people aged 18 to 65 found the reverse results (in-
creased mortality risk for women with SBP/DBP ≥130/85 mm Hg
but not for men) (29). Evidence from Chinese cohort studies (6,7)
indicated high mortality risk for men with SBP <100 mm Hg/120
mm Hg. For women, these studies showed high mortality risk with
SBP ≥140 mm Hg/160 mm Hg, DBP ≥90 mm Hg, and SBP/DBP
140/90 mm Hg or even 160/100 mm Hg. Participants in these
Chinese studies were coal miners and urban women.
Our study suggested an association of all-cause mortality for men
with high SBP (≥120 mm Hg) and high DBP (≥90 mm Hg), or
SBP/DBP ≥130/80 mm Hg, but not for women. The possible ex-
planations for inconsistencies between our results and previous
studies may be differences in socioeconomic status, demographic
and physiologic characteristics, genetic predisposition, lifestyles,
and environmental  factors in multi-ethnic populations (11,30).
Also, excessive lowering of blood pressure with the use of anti-
hypertension medications would causally increase the risk of all-
cause mortality (31), but previous studies ignored the effect of an-
tihypertension medication apart from regarding it as a potential
confounder. Only 1 study excluded people receiving antihyperten-
sion agents, but participants in that study were mainly young men
aged 18 to 39 (26).
Our study showed a difference by sex in the blood pressure–mor-
tality relationship. One explanation is that men could have greater
psychological distress associated with mortality than women, a
phenomenon more prevalent in poor regions, as in our rural study,
than in urban areas (32,33). Also, the interaction between sex and
genetic factors could be responsible for the different blood pres-
sure–mortality association in men and women (34). Additionally,
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T cells play an important role in the pathogenesis of hypertension
and are associated with a sex difference (35). High blood pressure
is a major cause of cardiovascular disease mortality and a major
contributor to all-cause mortality (36). Low blood pressure is asso-
ciated with decreased myocardial perfusion pressure and myocar-
dial ischemia (37). In addition, low blood pressure increases arteri-
al stiffness, which increases mortality risk (38). The explanation
for the association between blood pressure and risk of all-cause
mortality is not intuitive, and the relevant mechanism should be
further explored (36). Another possible reason may be different
physiologic factors (39). However, we have no evidence of the rel-
ative benefits and harms of lowering blood pressure to recommen-
ded  targets  varying  as  a  function  of  sex  (40),  and  treatment
guidelines are consistent for men and women (11,12).
Our study results suggest an association of blood pressure accord-
ing to the 2017 US hypertension guidelines with all-cause mortal-
ity in rural Chinese adults and provide a useful reference for fu-
ture studies. Lowering blood pressure to 130/80 mm Hg could be
achieved by early hypertension screening and intervention (includ-
ing active intervention in lifestyle), and the benefit may be greater
among Asians than Westerners (30). The hypertension prevalence
among rural Chinese in our study was 3 times higher according to
the 2017 US hypertension guidelines (47.1% for men and 46.1%
for  women)  than according to  the  2018 Chinese  hypertension
guidelines (14.5% for men and 15.4% for women). The number of
antihypertension treatments cannot increase significantly, and non-
pharmacologic interventions, especially reducing salt intake and
body weight, still remain a fundamentally important approach to
hypertension control (11,30). Treatment could rely on clinicians’
cautious judgment about whether and when to start antihyperten-
sion treatment. In addition, setting goals for high blood pressure
prevention and control may need to be tailored to people and pop-
ulations with differing characteristics (27). Moreover, the aware-
ness,  treatment,  and  control  rates  of  hypertension  are  low  in
China; a transition from knowing the problem to implementing the
solution and improving management of medical therapy for hyper-
tension is needed (30,41,42).
The primary strength  of  our  study is  its  being the  first  to  our
knowledge to evaluate the association between the 2017 US hy-
pertension guidelines and all-cause mortality in a Chinese popula-
tion. Its second strength is its prospective design based on a gener-
al population with 81,856 person years of follow-up and the stand-
ardized longitudinal assessment of blood pressure and well-meas-
ured covariates. Finally, we assessed the sex-specific blood pres-
sure–mortality relationship, whereas we previously had little evid-
ence on the association of blood pressure categories with all-cause
mortality by sex in China.
Nevertheless, our study has limitations. First, the generalizability
of our findings to urban or to other ethnic populations than those
in our study may be limited because study participants were rural
Chinese  adults.  Second,  despite  sensitivity  analyses  of  parti-
cipants who had none of the 5 pre-existing chronic diseases, we
could not completely exclude people with all chronic medical con-
ditions. Finally, the possibility of residual confounding bias may
remain because some covariates, such as psychological factors,
were not investigated. Further studies are needed to evaluate sex
differences  in  lowering  blood  pressure  to  an  optimal  level.
Moreover, blood pressure–attributable mortality is a major public
health  challenge,  and  the  combined  efforts  of  health-policy
makers, health care providers, and the general population are re-
quired to reduce the mortality burden caused by elevated blood
pressure and hypertension.
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Table
Table. Baseline Characteristics of Study Participants by Mortality Status, the Rural Chinese Cohort Study, 2007–2014a
Variable Total (N = 13,760) Survivors (n = 13,050) Decedents (n = 710) P Value
Men 5,661 (41.1) 5,233 (40.1) 428 (60.3) <.001
Age, y, median (IQR) 49.0 (40.0–59.0) 49.0 (40.0–58.0) 65.0 (57.0–73.0) <.001
Married or cohabitating 12,460 (90.6) 11,920 (91.3) 540 (76.1) <.001
Mean individual income, monthly, CNY
<500 12,792 (93.2) 12,108 (92.8) 684 (96.3)
.001500–1,000 744 (5.4) 722 (5.5) 22 (3.1)
≥1,000 191 (1.4) 189 (1.4) 2 (0.3)
Education level high school or above 1,536 (11.2) 1,505 (11.5) 31 (4.4) <.001
Smokedb 3,953 (28.7) 3,689 (28.3) 264 (37.2) <.001
Drank alcohol 1,745 (12.7) 1,676 (12.8) 69 (9.7) .02
Physical activity
Low 4,049 (29.4) 3,685 (28.2) 364 (51.3)
<.001Moderate 2,940 (21.4) 2,834 (21.7) 106 (14.9)
High 6,771 (49.2) 6,531 (50.1) 240 (33.8)
BMI (kg/m2), median (IQR) 23.6 (21.4–26.1) 23.7 (21.4–26.1) 22.6 (20.8–25.2) <.001
Systolic blood pressure, mm Hg, median (IQR) 119.0 (109.3–130.0) 118.7 (109.0–129.7) 126.3 (115.3–141.7) <.001
Diastolic blood pressure, mm Hg, median (IQR) 75.3 (69.3–82.0) 75.3 (69.3–82.0) 76.3 (69.0–84.3) .046
Total cholesterol, mmol/L, median (IQR) 4.3 (3.8–5.0) 4.3 (3.8–5.0) 4.5 (3.9–5.1) .008
Triglycerides, mmol/L, median (IQR) 1.3 (0.9–1.9) 1.3 (0.9–1.9) 1.3 (0.9–1.8) .08
HDL cholesterol, mmol/L, median (IQR) 1.1 (1.0–1.3) 1.1 (1.0–1.3) 1.1 (1.0–1.3) .009
LDL cholesterol, mmol/L, median (IQR) 2.5 (2.0–3.0) 2.5 (2.0–3.0) 2.6 (2.2–3.1) <.001
Fasting plasma glucose, mmol/L, median (IQR) 5.3 (5.0–5.7) 5.3 (5.0–5.7) 5.4 (5.0–6.0) <.001
Abbreviations: BMI, body mass index; CNY, Chinese Yuan; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein.
a Calculated at a mean follow-up of 5.95 years (81,856 person years). Values are number (percentage) unless otherwise indicated.
b Defined as currently smoking and/or having smoked 100 or more cigarettes during their lifetime.
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Appendix
Appendix. Table 1. Baseline Characteristics of People Included and Excluded, the Rural Chinese Cohort Study, 2007–2014
Variables Included, n = 13,760 Excluded, n = 6,434 P Value
Men 5,661 (41.1) 2,272 (35.3) <.001
Age, y, median (IQR) 49.0 (40.0–59.0) 55.0 (44.0–64.0) <.001
Married/cohabitating 12,460 (90.6) 5,436 (84.5) <.001
Mean individual monthly income
<500 CNY 12,792 (93.2) 5,889 (91.9)
.003500–1,000 CNY 744 (5.4) 420 (6.6)
≥1,000 CNY 191 (1.4) 102 (1.6)
High school diploma or above 1,536 (11.2) 722 (11.2) .90
Smoking 3,953 (28.7) 1,429 (22.2) <.001
Drinking 1,745 (12.7) 556 (8.6) <.001
Physical activity
Low 4,049 (29.4) 2,812 (43.7)
<.001Moderate 2,940 (21.4) 1,339 (20.8)
High 6,771 (49.2) 2,283 (35.5)
BMI, kg/m2, median (IQR) 23.6 (21.4–26.1) 24.7 (22.2–27.5) <.001
SBP, mm Hg, median (IQR) 119.0 (109.3–130.0) 134.3 (118.0–152.3) <.001
DBP, mm Hg, median (IQR) 75.3 (69.3–82.0) 82.7 (74.0–92.0) <.001
Total cholesterol, mmol/L, median (IQR) 4.3 (3.8–5.0) 4.5 (3.9–5.2) <.001
Triglycerides, mmol/L, median (IQR) 1.3 (0.9–1.9) 1.5 (1.0–2.2) <.001
HDL-C, mmol/L, median (IQR) 1.1 (1.0–1.3) 1.1 (1.0–1.3) .002
LDL-C, mmol/L, median (IQR) 2.5 (2.0–3.0) 2.6 (2.1–3.1) <.001
Fasting plasma glucose, mmol/L, median (IQR) 5.3 (5.0–5.7) 5.4 (5.1–5.9) <.001
Abbreviations: BMI, body mass index; CNY, Chinese Yuan; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol;
LDL-C, low-density lipoprotein cholesterol; IQR, interquartile range; SBP, systolic blood pressure.
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Appendix. Table 2. All-Cause Mortality Risk by Blood Pressure Categories at Baseline Examination for Men And Women, the Rural Chinese Cohort Study,
2007–2014a
Categories
Men Women
aHR (95% CI) aHR (95% CI)
Systolic blood pressure, mmHg
<100 1.51 (0.93–2.45) 1.46 (0.90–2.38)
100–119 1 [Reference] 1 [Reference]
120–139 1.41 (1.10–1.80) 0.91 (0.67–1.23)
≥140 2.00 (1.51–2.66) 1.15 (0.82–1.60)
Diastolic blood pressure, mmHg
<70 0.98 (0.76–1.26) 1.07 (0.79–1.46)
70–79 1 [Reference] 1 [Reference]
80–89 1.30 (1.01–1.67) 1.15 (0.84–1.58)
≥90 1.57 (1.13–2.18) 1.50 (1.02–2.21)
Systolic blood pressure/diastolic blood pressure, mmHg
<120/80 1.80 (1.31–2.48) 1.12 (0.77–1.62)
120–129/<80 1 [Reference] 1 {Reference]
130–139/80–89 1.49 (1.11–1.99) 0.75 (0.51–1.12)
≥140/90 1.52 (1.18–1.95) 1.01 (0.75–1.36)
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval.
a Adjusted for age, marital status, mean individual income (monthly), education level, smoking, drinking, physical activity, body mass index, total cholesterol,
triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, diabetes mellitus, family history of diseases
(hypertension, diabetes mellitus, and hyperlipidemia), and use of medications (hypoglycemic and lipid-lowering agents).
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Appendix. Table 3. All-Cause Mortality Risk by Blood Pressure Categories at Baseline Examination for Men and Women on Sensitivity Analyses, the Rural Chinese
Cohort Study, 2007–2014a
Category
Men Women
aHR (95% CI) aHR (95% CI)
Systolic blood pressure, mmHg
<100 1.90 (1.08–3.35) 1.68 (1.00–2.83)
100–119 1 [Reference] 1 [Reference]
120–139 1.71 (1.25–2.32) 0.92 (0.65–1.30)
≥140 2.55 (1.80–3.62) 1.17 (0.80–1.72)
Diastolic blood pressure, mmHg
<70 0.90 (0.66–1.22) 1.05 (0.74–1.48)
70–79 1 [Reference] 1 [Reference]
80–89 1.29 (0.95–1.75) 1.07 (0.74–1.54)
≥90 1.72 (1.16–2.54) 1.55 (1.00–2.39)
Systolic blood pressure/diastolic blood pressure, mmHg
<120/80 2.29 (1.55–3.38) 1.09 (0.71–1.67)
120–129/<80 1 [Reference] 1 [Reference]
130–139/80–89 1.73 (1.21–2.46) 0.69 (0.43–1.09)
≥140/90 1.84 (1.35–2.50) 0.94 (0.67–1.31)
Abbreviations: aHR, adjusted hazard ratio; CI, confidence interval.
a Sensitivity analyses excluding study participants who died during the first 2 years of follow-up and who had chronic disease at baseline examination (myocardial
infarction, heart failure, stroke, or cancer. Adjusted for age, marital status, mean individual income (monthly), education level, smoking, drinking, physical activity,
body mass index, total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting plasma glucose, diabetes mellitus,
family history of diseases (hypertension, diabetes mellitus, and hyperlipidemia), and use of medications (hypoglycemic and lipid-lowering agents).
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